Navigation Links
CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
Date:7/22/2008

PALO ALTO, Calif., July 22 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release second quarter financial results for 2008 after the market closes on Thursday, July 31, 2008. Company management will webcast a conference call at 5:00 p.m. EDT, 2:00 p.m. PDT, on the company's website.

To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6241, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Thursday, August 7, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 56235490.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequa
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Recognizing exciting ... faculty members to its 2013 Class of Young ... company will provide this outstanding international group with ... advancing basic science to meet global challenges.     , ... help promising young and untenured research faculty working ...
(Date:5/19/2013)... Switzerland’s MS Tûranor PlanetSolar , ... speed record for a transatlantic crossing by a solar ... April 25, 2013, the solar powered boat sailed 2,867miles ... speed of 5.3 knots before reaching Marigot, St. Martin, ... The first-of-its-kind catamaran completed this year’s passage across the ...
(Date:5/17/2013)... when the transplant recipient,s immune system identifies the transplanted ... previously thought that T cells, the immune cells that ... as chemokines in order to migrate to the transplanted ... Clinical Investigation , Fadi Lakkis and colleagues at the ... stimulation of T cells is not required for migration. ...
(Date:5/17/2013)... PHILADELPHIA , May 17, 2013 ... held by the most innovative thought leaders of ... Device & Manufacturing East conference and expo, from ...      (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) ... were designed to deliver industry professionals practical presentations ...
Breaking Biology Technology:DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2
... JERUSALEM , May 18, 2010 ... MD, joins Oramed,Pharmaceuticals, Board of Directors. Dr. Berelowitz is currently Senior Vice,President ... Unit at Pfizer, Inc., the world,s largest,research-based pharmaceutical company. , ... Dr. Berelowitz joined ...
... Pfizer Global Manufacturing announced today plans to reconfigure its ... supply organization from the combined networks of Pfizer (NYSE: ... phase of Pfizer,s previously announced Plant Network Strategy includes recommendations ... , Puerto Rico , and the United States ...
... 2010 , , , ... , , , ... cleared by FDA for Home/Self use and is,consequently available to all patients with home hemodialysis ... use has already improved in-clinic patient,safety. Optimizing safety conditions for home hemodialysis users is a ...
Cached Biology Technology:Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors 2Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors 3Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 2Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 3Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 4Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 5Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 6Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 7Redsense Medical Receives FDA Clearance for the Redsense Safety Device for Home/Self use During Home Hemodialysis 2
(Date:5/16/2013)... 17, 2013) Illustrating a commitment to the ... Gastroenterological Association (AGA) Research Foundation has announced the ... Fellowship Award recipients. Supported by the National Institute ... this new award helps underrepresented minority students to ... nutrition research. , "By establishing this new award, ...
(Date:5/16/2013)... closer to a fast food restaurant had a higher ... away from fast food, according to researchers at The ... association was particularly strong among those with a lower ... the American Journal of Public Health indicates ... food restaurant, and among lower-income African-Americans, the density, or ...
(Date:5/16/2013)... nanoparticles developed at MIT may someday eliminate the ... constantly monitor their blood-sugar levels and inject themselves ... sense glucose levels in the body and respond ... replacing the function of pancreatic islet cells, which ... Ultimately, this type of system could ensure that ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... Zurich, Switzerland, August 18, 2009 / b3c newswire ... that, following the successful completion of key research ... disease has advanced into preclinical development, triggering milestone ... (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for ...
... Why is it that you can instantly recall your own phone ... a new number you heard a few moments ago? The two ... long-term and short-term, respectively that are stored very differently ... the animal kingdom, even in insects such as the fruit fly. ...
... by lightning strikes, Victor Ugaz, associate professor in the ... University, has created a network of microchannels that could ... a three-dimensional vasculature for the support of larger tissue ... undertaken with colleague Arul Jayaraman and appears in the ...
Cached Biology News:Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 2Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 3CSHL study finds short- and long-term memories require same gene but in different circuits 2CSHL study finds short- and long-term memories require same gene but in different circuits 3Researcher says microchannels could advance tissue engineering methods 2Researcher says microchannels could advance tissue engineering methods 3Researcher says microchannels could advance tissue engineering methods 4
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Biology Products: